[Meeting Abstract] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Sikic BI, Wakelee HA, Von Mehren M, Lewis NL, Plummer ER, Calvert AH, Fox NL, Kumm EA, Jones SF, Burris HA

Publication type: Article

Publication status: Published

Journal: Molecular Cancer Therapeutics

Year: 2007

Volume: 6

Issue: 12

Pages: 3454S-3455S

ISSN (print): 1535-7163

ISSN (electronic): 1538-8514

Publisher: American Association for Cancer Research

ePrints